Effects of the 5 HT(1A) receptor agonist flesinoxan in panic disorder

Psychopharmacology

Volumn 127, Issue 2, 1996, Pages 174-180

  Van Vliet, Irene M ^a   Westenberg, Herman G M ^a   Den Boer, Johan A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

5 HT(A) agonist; Agoraphobia; Anxiety; Flesinoxan; Human studies; Panic disorder

Indexed keywords

FLESINOXAN; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; ANXIOLYTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MOOD; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SYMPTOM; VERTIGO; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PIPERAZINES; SEROTONIN AGONISTS; SINGLE-BLIND METHOD;

EID: 0029658394     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. American Psychiatric Association (1987) Diagnostic and statistic manual of menial disorders, 3rd edn, revised. Washington APA, DC
2. Bel N, Artigas F (1991) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: in vivo microdialysis study. Eur J Pharmacol 229:101-103
3. Borison RL, Albrecht JW, Diamond BI (1990) Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 26:207-210
4. Bradford LD, Stevens G (1994) Double-blind placebo controlled fixed does studies of flesinoxan in generalized anxiety disorders. Abstract of the American College of Neuropsychopharmacology, Puerto Rico, p 167
5. Briley M, Chopin P, Morel C (1991) The role of scrolonin in anxiety: behavioural approaches. In: Briley M, File SE (eds) New concepts in anxiety. MacMillan, London, pp 56-73
6. Chaput Y, Blier P, de Monligny C (1988) Acute and long-term effects of antidepressant serotonin (5-HT) uptake blockers on the efficacy of 5-HT neurotransmission. Electrophysiological studies in the rat. Adv Biol Psychiatry 17:1-17
7. Chaput Y, de Monligny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonergic system by long-cerm administration of antidepressant treatmenls. Neuropsychopharmacology 5:219-229
8. De Monligny C, Blier P (1992) Electrophysical properties of 5-HT-1A receptors and 5-HT-1A agonists. In: Stahl S, Gastpar M, Keppel Hesselink JM et al. (eds) Serotonin 1A receptors in depression and anxiety. Raven Press, New York, pp 83-98
9. Den Boer JA, Westenberg HGM (1988) Effects of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maproliline. Int Clin Psychopharmacol 3:59-74
10. Den Boer JA, Westenberg HGM (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85-94
11. Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS (1987) Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipraminc and fluvoxamine. Int Clin Psychopharmacol 2:21-32
12. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
13. Frazer GA, Lapierre YD (1987) The effect of buspirone on panic disorder: a case report. J Clin Psychopharmacol 7:118-119
14. Fux M, Taub M, Zohar J (1993) Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Ada Psychiatr Sound 88: 235-237
15. Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993) An open study of oral flesinoxan, a 5-HT-1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 8:167-172
16. Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Dept of Health, Education and Welfar, Rockville, Maryland, pp 337-340
17. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
18. Harto NF, Branconnier RJ, Spera KF (1988) Clinical profile of gepirone: a non-benzodiazepine anxiolytic. Psychopharmacol Bull 24:154-160
19. Invernizzi R, Belli S, Samamanti R (1991) Citalopram's ability to increase the extracellular concentration of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584:322-325
20. 1A receptors. Eur J Pharmacol 260:243-246
21. Johnston DG, Trover IE, Whitstett SF (1988) Clomipramine in the treatment of agoraphobic woman. Biol Psychiatry 25:101
22. Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-De Wied CC (1987) Effects of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 2:23-45
23. Kahn RS, Wetzler S, Van Praag HM, Asnis GM (1988a) Behavioral indications of serotonin receptor hypersensitivity in patients with panic disorder. Psychiatry Res 25:101-104
24. Kahn RS, Wetzler S, Van Praag HM, Asnis GM (1988b) Neuroendocrine evidence for serotonin receptor hypersensitivity in patients with panic disorder. Psychopharmacology 96:360-364
25. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder comparison to caffeine's anxiogenic effects. Biol Psychiatry 30: 973-984
26. 1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106:111-117
27. Mavissakalian M (1986) The fear questionnaire: a validity study. Behav Res Ther 24:83-85
28. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 34:382-389
29. Pecknold JC (1994) Serotonin 5-HT-1A agonists; a comparative review. CNS Drugs 2 [3]:234-251
30. Pecknold JC, Matas M, Howarth BG (1989) Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 34:766-774
31. Peeknold JC, Luthe L, Scott-Fleury MH, Jenkins S (1993) Gepirone in the treatment of panic disorder: an open study. J Clin Psychopharmacol 13 [2]:145-149
32. Pohl R, Balon R, Yeragani VK, Gershon S (1989) Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 22 [suppl. 1]:60-67
33. Riekels K, Weisman K, Norslad N (1989) Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43:81-86
34. Robinson DS, Shrotriya RC, Alms DR, Messina M, Andary J (1989) Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull 25 [1]: 21-26
35. Schipper J, Tulp MTM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of flesinoxan: a potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:53-61
36. Schweizer E, Riekels K (1988) Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate. J Clin Psychopharmacol 8:303
37. 1 agonists reduce 5-HT release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96:283-290
38. Sheehan D, Raj AB, Harnett Sheehan K, Soto S (1988) The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 29:815-817
39. Shechan D, Raj A, Sheehan K, Soto S (1990) Is buspirone effective for panic disorder? J Clin Psychopharmacol 10:3-11
40. Shechan D, Raj A, Harnett Sheehan K, Soto S, Knapp E (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1-11
41. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA (1982) The clinical anxiety scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 141:518-523
42. Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295-306
43. Westenberg HGM, Den Boer JA (1994) The neuropharmacology of anxiety: a review on the role of serotonin. In: Den Boer JA, Sitsen JMA (eds) Handbook of depression and anxiety: a biological approach. Marcel Dekker, New York, Basel, Hong Kong, pp 405-446
44. Zitrin C, Klein D, Woerner M, Ross D (1983) Treatment of phobias. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 40:125-138